Transforming the gene therapy landscape
with AI-powered AAV vectors

The Outlook

Gene therapies of the future will be designed using artificial intelligence (AI) to reach more patients and treat many more diseases.

Our Solution

Dyno Therapeutics is applying AI technology to discover novel gene therapy vectors with transformative delivery properties for a vast landscape of human diseases.

OUR SCIENCE

Read about our scientists' publications in Science, Nature Biotechnology, at ASGCT and more.

SERIES A FINANCING

Dyno closes $100 million Series A financing led by Andreessen Horowitz

PARTNERING & LICENSING

Astellas for AAV vectors directed to skeletal and cardical muscle

Roche for AAV vectors directed to CNS and liver

Sarepta for next-gen gene therapy vectors for muscle disease

Novartis for ocular collaboration to develop improved gene therapies

ANNOUNCEMENTS

Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence

AWARDS

2023 & 2022 FORBES LIST: AMERICA’S BEST STARTUP EMPLOYEER
For the second year in a row, Dyno is recognized on the Forbes list of America’s Best Startup Employers

NEVY AWARDS
Dyno named Emerging Company of the Year by the New England Venture Capital Association

ENDPOINTS NEWS
Dyno named one of the most promising startups of 2021

Back to Top